1h
Qatar Tribune on MSNExperts tackle global obesity rates, solutions at Qatar Int’l Metabolic and Bariatric SummitTribune News NetworkDohaWith obesity rates rising worldwide, the 4th Qatar International Metabolic and Bariatric Summit (4th QIMBS 2025), hosted by Hamad Medical Corporation (HMC), addressed the ...
Obesity affects more than 14 million children in the US. Typically, in adults, obesity is expressed by body mass index (BMI), ...
Scarring is expected after most operations, but surgical adhesions present a unique challenge for patients and surgeons.
In New York, 40% of Black Americans and 28% of white Americans are diagnosed with high blood pressure.
“For women with PCOS, regular physical activity and a balanced diet can aid in weight management, reducing the risk of obesity-related complications,” she said. “While lifestyle changes may ...
Atherosclerosis is when plaque builds up in the arteries, potentially blocking blood flow and leading to cardiovascular complications ... This was followed by advancing age, hypertension and obesity,” ...
18d
Stacker on MSNCan winter cause erectile dysfunction?Ro dives into the link between winter and erectile dysfunction, including reasons why it happens and possible solutions.
Childhood obesity has been on the rise in the United States for over a decade, and, according to the American Heart Association (AHA), approximately one in three children and teenagers lives with ...
These new weight loss drugs have shown promising results in reducing obesity and related complications like type 2 diabetes and cardiovascular disease. If made accessible and affordable ...
The studies featured in this Research Topic illuminate the multifaceted effects and mechanisms of bariatric surgery, particularly focusing on Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG ...
Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe’s most valuable listed company almost 5 per cent higher.
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results